Progressive cardiovascular disease in a patient under treatment with nilotinib
Clin Investig Arterioscler. 2020 Mar-Apr;32(2):66-69.
doi: 10.1016/j.arteri.2019.05.002.
Epub 2019 Jul 4.
[Article in
English,
Spanish]
Affiliations
- 1 Unidad de Riesgo Vascular, Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, España. Electronic address: ricardoroa@gmail.com.
- 2 Servicio de Cardiología, Hospital Universitario Virgen de las Nieves, Granada, España.
- 3 Unidad de Riesgo Vascular, Medicina Interna, Hospital Universitario Virgen de las Nieves, Granada, España.
- 4 Servicio de Hematología y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, España.
Abstract
The development of cardiovascular disease appears in subjects with several cardiovascular risk factors. However, other agents could be related to the appearance of cardiovascular disease, like chemotherapy drugs. We present a 63 years-old man with very high cardiovascular risk and chronic myeloid leukemia under treatment with nilotinib. Despite a good control of cardiovascular risk factors, he development a severe and accelerated peripheral arterial disease. Peripheral arterial disease occurs in 5-20% patients under treatment with nilotinib and it is more frequently in subjects with several cardiovascular risk factors.
Keywords:
Chronic myeloid leukaemia; Enfermedad arterial periférica; Leucemia mieloide crónica; Nilotinib; Peripheral arterial disease.
Copyright © 2019 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Cardiovascular Diseases / chemically induced*
-
Disease Progression
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Male
-
Middle Aged
-
Peripheral Arterial Disease / chemically induced*
-
Peripheral Arterial Disease / physiopathology
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects*
-
Severity of Illness Index
Substances
-
Antineoplastic Agents
-
Pyrimidines
-
nilotinib